TACSTD2 and neoplasm: Currently, the target antigens of approved ADC drugs are primarily specific proteins overexpressed on typical tumor cells, such as HER2, TROP-2, and nectin-4 in solid tumors, and CD19, CD22, CD33, and CD30 in hematologic malignancies (19, 111).